Kevin G Pinney

USPTO Granted Patents = 22 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 3.9

ph-index = 6

Forward Citations = 131(Granted Patents)

Location History:

Hewitt, TX (US) (1999 - 2003)
Woodway, TX (US) (2005 - 2018)
Waco, TX (US) (2020)

Company Filing History:

Mateon Therapeutics, Inc.

patents

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2020

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10807932 - Benzosuberene analogues and related compounds with activity as anticancer agents (2020-10-20),

2. 9873668 - Compositions and methods for inhibition of cathepsins (2018-01-23),

3. 9458103 - Compositions and methods for inhibition of cathepsins (2016-10-04),

4. RE45907 - Functionalized stilbene derivatives as improved vascular targeting agents (2016-02-29),

5. RE45720 - Functionalized stilbene derivatives as improved vascular targeting agents (2015-10-05),

6. 8877967 - Compositions and methods for inhibition of cathepsins (2014-11-04),

7. 8394859 - Combretastatin analogs with tubulin binding activity (2013-03-12),

8. 8198302 - Compositions and methods with enhanced therapeutic activity (2012-06-12),

9. 8173696 - Inhibitors of cysteine proteases and methods of use thereof (2012-05-08),

10. 7893261 - Serotonin reuptake inhibitors (2011-02-22),

11. 7456214 - Chromene-containing compounds with anti-tubulin and vascular targeting activity (2008-11-25),

12. 7429681 - Combretastatin analogs with tubulin binding activity (2008-09-30),

13. 7384925 - Functionalized stilbene derivatives as improved vascular targeting agents (2008-06-10),

14. 7091240 - Tubulin binding ligands and corresponding prodrug constructs (2006-08-15),

15. 7001926 - Tubulin binding agents and corresponding prodrug constructs (2006-02-21),

Title: Innovations and Contributions of Kevin G. Pinney in Anticancer Research

Introduction

Kevin G. Pinney is a notable inventor based in Woodway, TX, who has made significant contributions to the field of anticancer research. With a remarkable portfolio of 22 patents, he has paved the way for innovative therapeutic solutions that address various challenges in the treatment of cancer. His inventive work particularly focuses on compounds that inhibit essential proteins involved in cancer progression.

Latest Patents

Among his latest patents, one significant invention is the development of benzosuberene analogues and related compounds that exhibit activity as anticancer agents. These compounds have demonstrated effective inhibition of tubulin polymerization, showcasing cytotoxicity against human cancer cell lines and causing vascular disruption in tumors. Another patent focuses on compositions and methods for inhibition of cathepsins, particularly cathepsin K and cathepsin L, to treat conditions where modulation of these proteins is therapeutically beneficial.

Career Highlights

Throughout his career, Kevin G. Pinney has collaborated with prestigious institutions such as Baylor University and Oxigene, Inc., contributing to cutting-edge research and development in cancer therapeutics. His work is characterized by a strong commitment to enhancing drug efficacy and safety through innovative approaches.

Collaborations

In his journey of discovery and innovation, Kevin has worked alongside talented co-inventors including David J. Chaplin and Klaus Edvardsen. These collaborations have enriched his research efforts and led to advancements that have the potential to transform cancer treatment paradigms.

Conclusion

Kevin G. Pinney's dedication to research and innovation in the field of cancer therapy is evident through his numerous patents and collaborative efforts. His work continues to inspire future developments in the medical and pharmaceutical industries, paving the way for new therapeutic strategies that could benefit countless patients facing cancer.

This text is generated by artificial intelligence and may not be accurate.